It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

Core Viewpoint - Chemed Corporation reported strong first-quarter 2025 earnings and revenue growth, but faced stock price decline due to concerns over gross margin contraction and Roto-Rooter segment performance [1][2][14]. Financial Performance - Adjusted EPS for Q1 2025 was $5.63, an increase of 8.3% year over year, surpassing the Zacks Consensus Estimate by 0.5% [1] - GAAP EPS was $4.86, reflecting a 14.6% increase from the previous year [1] - Revenues for the quarter reached $646.9 million, up 9.8% year over year, exceeding the Zacks Consensus Estimate by 1.7% [2] Segment Performance - VITAS segment reported net patient revenues of $407.4 million, a 15.1% increase year over year, driven by an 11.9% rise in days-of-care and a 3.2% increase in Medicare reimbursement rates [4] - Roto-Rooter segment generated sales of $239.5 million, a 1.8% year-over-year increase, with commercial revenues up 7.3% [6] - Roto-Rooter residential revenues decreased by 1.7% year over year, with specific declines in drain cleaning and plumbing services [7] Margin and Expense Analysis - Gross profit increased by 6% year over year to $216.4 million, but gross margin contracted by 119 basis points to 33.5% due to rising service costs [8] - SG&A expenses decreased by 8.9% year over year to $105.6 million, while adjusted operating profit rose by 25.6% to $110.8 million [8] Liquidity and Capital Structure - As of the end of Q1 2025, the company had cash and cash equivalents of $173.9 million, down from $178.4 million at the end of Q4 2024, with no current or long-term debt [9][10] - Net cash provided by operating activities was $32.7 million, compared to $84.5 million in the same period last year [10] Shareholder Returns and Guidance - The company repurchased 50,000 shares for $29.8 million, with approximately $225.6 million remaining under its share repurchase authorization [11] - For 2025, Chemed expects VITAS revenues to grow by 10.5% to 11.3%, while Roto-Rooter is forecasted to grow by 2.4% to 3.0% [12] - Adjusted EPS guidance for 2025 is set between $24.95 and $25.45, indicating an 8.8% growth over 2024 [13]

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) is expected to report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with a consensus EPS estimate of $0.14, reflecting a +16.7% change, and revenues projected at $2.73 billion, up 5.9% from the previous year [1][3]. Earnings Expectations - The stock price may increase if the actual earnings exceed expectations in the upcoming report scheduled for May 2, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.73% lower over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +106.62% for BrightSpring, suggesting analysts have become more optimistic about the company's earnings prospects [11]. - The company currently holds a Zacks Rank of 3, indicating a hold position, which suggests a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, BrightSpring exceeded the expected EPS of $0.19 by delivering $0.22, resulting in a surprise of +15.79%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13]. Industry Comparison - Another player in the Zacks Medical Services industry, Organon (OGN), is expected to report earnings of $0.92 per share, reflecting a year-over-year decline of -24.6%, with revenues projected at $1.54 billion, down 4.9% [17]. - Organon's consensus EPS estimate has been revised down by 1.7% over the last 30 days, and it currently has a negative Earnings ESP of -1.91%, making it difficult to predict a beat on the consensus EPS estimate [18].

Company Performance - Avantor, Inc. reported quarterly earnings of $0.23 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.22 per share a year ago [1] - The company posted revenues of $1.58 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.72%, and down from $1.68 billion year-over-year [2] - Over the last four quarters, Avantor has surpassed consensus EPS estimates three times but has topped consensus revenue estimates only once [2] Stock Movement and Outlook - Avantor shares have declined approximately 26.4% since the beginning of the year, compared to a decline of 6.8% for the S&P 500 [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates at $0.26 for the coming quarter and $1.05 for the current fiscal year, with revenues expected to be $1.65 billion and $6.63 billion respectively [7] Industry Context - The Medical Services industry, to which Avantor belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - The performance of Avantor's stock may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - The collaboration between Yuhang Second People's Hospital and local companies aims to enhance healthcare services for high-level talents in the Yuhang District, promoting a comprehensive health service system within enterprises [6][9][11] Group 1: Health Services Initiatives - Zhejiang Qiangnao Technology Co., Ltd. has signed a health cooperation agreement with Yuhang Second People's Hospital, allowing employees to access specialized medical services conveniently [6] - Yuhang Second People's Hospital has established partnerships with eight enterprises, creating a "health protection network" for over 3,000 high-level talents through various healthcare initiatives [6][9] - The establishment of embedded clinics, such as Fangzhong Zhihai Clinic, provides on-site medical services, addressing the healthcare needs of employees and their families [7][8] Group 2: Comprehensive Health Management - Yuhang Second People's Hospital offers a full-process health management system for corporate employees, including pre-examination education, real-time queue updates, and post-examination consultations [9] - The hospital's systematic approach to health management has resulted in high employee satisfaction and trust, leading to increased engagement in health services [9] Group 3: Technological Integration in Healthcare - The introduction of the 5G+ Health Wealth Direct Car enhances the efficiency of medical services, allowing employees to receive diagnoses and treatment within minutes [10] - The mobile health unit is equipped with advanced technology, enabling remote consultations and real-time health data sharing, thus improving the overall healthcare experience for employees [10][11] Group 4: Future Developments - Yuhang Second People's Hospital plans to expand its healthcare services by introducing drone delivery for medical supplies and blood samples, further enhancing the accessibility of healthcare [11] - The hospital aims to deepen its collaboration with enterprises to continuously improve the health service landscape for high-level talents, contributing to a better business environment in Yuhang [11]

Core Insights - Progyny (PGNY) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 10.81% [1][2] Earnings Performance - For the last reported quarter, Progyny achieved earnings of $0.42 per share, surpassing the Zacks Consensus Estimate of $0.37 per share, resulting in a surprise of 13.51% [2] - In the previous quarter, the company was expected to earn $0.37 per share but delivered $0.40 per share, yielding a surprise of 8.11% [2] Earnings Estimates and Predictions - Recent estimates for Progyny have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8] - The current Earnings ESP for Progyny is +2.68%, suggesting analysts are optimistic about its near-term earnings potential [8] Statistical Insights - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7]

Company Performance - Cencora (COR) has returned 27.6% year-to-date, significantly outperforming the Medical group, which has lost about 5.6% on average [4] - Cencora currently holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook [3] - Over the past 90 days, the Zacks Consensus Estimate for Cencora's full-year earnings has increased by 0.1%, reflecting improving analyst sentiment [3] Industry Context - Cencora is part of the Medical Services industry, which consists of 58 stocks and is currently ranked 86 in the Zacks Industry Rank, with an average loss of 3% this year [5] - In comparison, Intensity Therapeutics Inc. (INTS), another outperforming stock in the Medical sector, has returned 5.1% year-to-date and belongs to the Medical - Biomedical and Genetics industry, which has seen a decline of 7.7% [4][6] - The Medical group includes 1002 companies and is currently ranked 3 in the Zacks Sector Rank, which evaluates the average Zacks Rank of individual stocks within the sector [2]

Trade Policy Impact - The United States has implemented new tariffs, with a 10% baseline tariff on most imports and up to 145% on Chinese goods, significantly affecting global trade dynamics [1] - The elimination of the "de minimis" exemption for shipments under $800 impacts low-cost Chinese e-commerce platforms like Temu and Shein [1] - China has responded by suspending exports of critical minerals, escalating the trade conflict and increasing uncertainty in global markets [1] Economic Consequences - Previous tariffs from 2018 to 2020 resulted in over $80 billion in additional costs for American businesses and consumers, raising concerns about price increases and margin compression across industries [2] - The reintroduction of tariffs in 2025 has raised alarms in the corporate sector, particularly regarding the implementation timeline and potential retaliatory measures from trade partners like China [2] Pharmaceutical Sector - The U.S. government is preparing to impose tariffs on select pharmaceutical imports from countries like China and India, raising concerns about increased costs and supply chain disruptions [3] - Pharmaceutical companies, reliant on international manufacturing, are particularly vulnerable to trade disruptions, leading to a cautious sentiment in the industry [3] Medical Device Sector - The medical device sector is identified as a strong investment opportunity, driven by technological advancements, demographic trends, and increasing demand for healthcare solutions [4] - The global medical devices market was valued at $518.46 billion in 2023 and is projected to grow to over $886.80 billion by 2032, with a CAGR of 6.3% [5] Investment Opportunities - Amid tariff uncertainties, investors are focusing on undervalued stocks with strong balance sheets and resilient performance, particularly in the medical device sector [6] - Promising undervalued stocks for 2025 include Cencora, Inc. (COR), Hims & Hers Health (HIMS), and Prestige Consumer (PBH) [6] Cencora, Inc. - Cencora is a major pharmaceutical services company with a diverse portfolio, including biologics and complex injectables [7] - The company has launched Accelerate Pharmacy Solutions to optimize operations for healthcare customers and has acquired Retina Consultants of America to enhance its specialty leadership [8] - Cencora's stock trades at a P/S ratio of 0.17, lower than the Medical Services market's 0.40, with an expected 11.6% growth in 2025 earnings [9] Hims & Hers Health - Hims & Hers Health offers subscription-based telehealth services and aims to simplify healthcare through a digital-first platform [10] - The company has a P/S ratio of 2.47, discounted compared to the industry's 4.03, with a projected 58% growth in 2025 earnings [11] Prestige Consumer - Prestige Consumer provides over-the-counter healthcare products and has a strong presence across various retail channels [12] - The gastrointestinal product category is a significant growth driver, representing nearly one-fifth of North American sales [13] - The stock trades at a P/S ratio of 3.43, lower than the industry's 5.32, with a recent earnings surprise of 5.17% [16]

Core Viewpoint - Elevance Health (ELV) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The earnings report is scheduled for April 22, 2025, with expectations of quarterly earnings at $11.09 per share, reflecting a +4.2% year-over-year change, and revenues projected at $45.95 billion, an increase of 8.7% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.46% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Elevance Health is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.75%, suggesting a bullish outlook from analysts [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Elevance Health currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Elevance Health had an earnings surprise of +1.05%, having beaten consensus EPS estimates three times over the last four quarters [12][13]. Industry Context - Medpace (MEDP), another player in the Zacks Medical Services industry, is expected to report earnings of $3.06 per share, reflecting a -4.4% year-over-year change, with revenues projected at $530.12 million, up 3.7% from the previous year [17]. - Medpace's consensus EPS estimate has been revised down by 1.5% over the last 30 days, resulting in an Earnings ESP of -3.39%, making it challenging to predict a beat on the consensus EPS estimate [18].

Investors in Sotera Health Company (SHC) need to pay close attention to the stock based on moves in the options market lately. That is because the May 16, 2025 $10.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could ...